Hunan Jiudian Pharmaceutical Co., Ltd. Stock

Equities

300705

CNE1000034Z6

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-14 pm EDT 5-day change 1st Jan Change
35.66 CNY +1.54% Intraday chart for Hunan Jiudian Pharmaceutical Co., Ltd. +0.96% +7.31%
Sales 2023 * 2.83B 392M Sales 2024 * 3.53B 488M Capitalization 12.31B 1.7B
Net income 2023 * 380M 52.5M Net income 2024 * 495M 68.39M EV / Sales 2023 * 4.34 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 3.48 x
P/E ratio 2023 *
32.3 x
P/E ratio 2024 *
24.8 x
Employees 1,636
Yield 2023 *
0.39%
Yield 2024 *
0.5%
Free-Float 48.72%
More Fundamentals * Assessed data
Dynamic Chart
Hunan Jiudian Pharmaceutical Co., Ltd. Elects Yang Yang and Fan Pengyun as Non-Independent Director CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hunan Jiudian Pharmaceutical Co., Ltd.(XSEC:300705) added to S&P Global BMI Index CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Approves 2022 Final Profit Distribution, Payable on May 15, 2023 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Proposes Cash Dividend for the Year of 2022 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Hunan Jiudian Pharma Wins Nod to Trial Anti-Inflammatory Patch MT
Jiudian Pharma Sees FY22 Profit to Rise Up to 33.7% MT
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 27 May 2022 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021 CI
Nan Jiudian Pharmaceutical Announces Profit Distribution Plan for 2021 CI
More news
1 day+1.36%
1 week-2.93%
Current month-6.45%
1 month-4.17%
3 months+11.46%
6 months+39.42%
Current year+5.69%
More quotes
1 week
34.43
Extreme 34.43
36.00
1 month
34.43
Extreme 34.43
39.00
Current year
27.68
Extreme 27.68
39.00
1 year
18.80
Extreme 18.8
39.00
3 years
13.14
Extreme 13.1357
39.00
5 years
6.85
Extreme 6.85
39.00
10 years
4.44
Extreme 4.4429
39.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 02-12-31
Director of Finance/CFO 60 06-12-31
Director/Board Member 47 00-12-31
Members of the board TitleAgeSince
Chairman 61 00-12-31
Director/Board Member 60 00-12-31
Director/Board Member 57 00-12-31
More insiders
Date Price Change Volume
24-04-15 35.66 +1.54% 2,249,560
24-04-12 35.12 +1.36% 2,433,260
24-04-11 34.65 -1.28% 2,331,448
24-04-10 35.1 -1.63% 1,868,574
24-04-09 35.68 +1.02% 3,349,840

End-of-day quote Shenzhen S.E., April 11, 2024

More quotes
Hunan Jiudian Pharmaceutical Co., Ltd. is a China-based company mainly engaged in research and development, manufacture and sales of pharmaceutical products. The Company's main products can be divided into four categories: pharmaceutical preparations, pharmaceutical raw materials, pharmaceutical excipients and plant extracts. The Company's products include anti-infective drugs, anti-allergy drugs, digestive system drugs, respiratory drugs, cardiovascular and cerebrovascular drugs, gynecological drugs, tonic, patch and other fields. The Company's main product names include ornidazole tablets, erythromycin enteric-coated tablets, levocetirizine hydrochloride tablets, pantoprazole sodium enteric-coated tablets, hydrochloric acid bambuterol capsules, compound Nanwujia oral liquid, medicinal sucrose, medicinal ethanol and others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
35.66
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300705 Stock